Standard weight-based infliximab (IFX) dosing for inflammatory bowel disease (IBD) results in long-term clinical remission in only 40-60% of patients. Patient and disease factors account for variability in IFX exposure. Achieving optimal IFX exposure as assessed by pre-dose trough levels is associated with improved outcomes. Clinical tools are needed to personalize IFX dosing in a dynamic fashion.